What happened, in summary

This Noxte post focused on pathology details that complicated the patient’s understanding of his lung cancer. A bronchoscopy performed on 5 February had produced a biopsy report from Hospital Puerta de Hierro. The tumor had first been understood as adenocarcinoma, but the pathology description also mentioned infiltration by squamous carcinoma. That detail worried him because it suggested a mixed or more complicated tumor biology and made him less sure which targeted approach would be best. T790M resistance had later become negative in several liquid biopsies, which had kept him from entering the AZD9291 trial at that time. He continued taking afatinib/Giotrif and waited for the next CT planned for June, after about 5 months on the drug. He felt the only honest answer was to wait and see how the tumor behaved. Symptom control mattered just as much in daily life. Cough, shortness of breath, and chest pain were better controlled with codeine plus ibuprofen, enough that he was considering a trip to Seville. As of 8 May 2016, he was still in active treatment, balancing hope from symptom improvement with concern that the tumor’s squamous-cell component could make the path ahead harder.